The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing Manufacture Of Chemicals And Pharamceuticals Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations 21.2 - Manufacture of pharmaceutical preparations
250 jobs Number of planned job creations
Announcement Date
7 November 2018
Employment effect (start)
7 November 2018
Foreseen end date
6 November 2019
Description
The Anglo-Swedish pharmaceutical and biopharmaceutical company AstraZeneca has announced plans to create 250 new positions at its units in Warsaw. AstraZeneca is mainly looking for IT and statistics specialists. Most of the new employees will work in the research and development centre, which focuses on research and medicine testing. The company has also revealed that more than PLN 1.5 billion (€349.6 million) will be invested by the end of 2022 in the Polish market. As of November 2018, AstraZeneca operates across 100 countries and employs around 51,700 staff globally.
Sources
Citation
Eurofound (2018), AstraZeneca, Business expansion in Poland, factsheet number 95934, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/95934.
Digitisation and automation technologies, including artificial intelligence (AI), can affect working conditions in a variety of ways and their use in the workplace raises a host of new ethical concerns.
The retail banking sector is fertile ground for studying the impacts of digitalisation on work and employment. Financial services are increasingly provided online, without the intermediary of customer-facing institutions.
European labour markets have recovered strongly from COVID-19. By the end of 2021, little more than 18 months after the start of the pandemic, employment rates in the EU were almost at pre-crisis levels.
